14 stories tagged with #regeneron, in publish-time order across the WeSearch catalog. Tag pages update as new stories ingest.
⌘ RSS feed for this tag → or search "Regeneron"
Regeneron Q2 Earnings Preview: Not Expecting Miracles - At Least In The Short Term
Regeneron (REGN) is a Buy ahead of Q2 2026 earnings: Dupixent, Eylea HD, and Libtayo growth plus pipeline catalysts and $3B buyback. Read the latest analysis on the stock here.…
U.S. biotech giant Regeneron chooses Hyderabad to set up GCC
Regeneron Pharmaceuticals plans to set up a global capability centre in Hyderabad, with operations starting in 2026 and hundreds of jobs expected in coming years.…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN - Morningstar
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
Apogee Therapeutics: Targeting Atopic Dermatitis
Apogee Therapeutics, Inc. is rated a Hold, driven by promising data for the lead asset zumilokibart in atopic dermatitis. Read more on APGE stock here.…
Jim Cramer on Regeneron: “There Could Be Some More Downgrades”
Canaccord lowers Regeneron stock price target on pipeline concerns
The Surprising Reason Regeneron Pharmaceuticals Just Dropped 10%
Regeneron: Time To Forget Fianlimab (Rating Upgrade)
Regeneron is rated a Buy due to stronger growth, an expanding and maturing pipeline, and a strong balance sheet. Read more on REGN stock here.…